| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/100-1/200 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human PRKCB |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与PRKCB抗体相关的文献概览：
---
1. **文献名称**: *"Protein kinase C β inhibition attenuates diabetic retinopathy through suppression of retinal inflammation"*
**作者**: Koya D, et al.
**摘要**: 研究利用PRKCB特异性抗体(如LY333531)在小鼠模型中验证PKCβ抑制剂对糖尿病视网膜病变的治疗作用，发现抑制PKCβ可减少血管渗漏和炎症因子表达。
---
2. **文献名称**: *"PKCβ promotes melanoma metastasis by phosphorylating and activating αvβ3 integrin"*
**作者**: Ikenoue T, et al.
**摘要**: 通过PRKCB抗体进行Western blot和免疫荧光实验，证明PKCβ通过磷酸化整合素αvβ3驱动黑色素瘤转移，靶向PKCβ可抑制侵袭性表型。
---
3. **文献名称**: *"PKCβ regulates tau phosphorylation and synaptic dysfunction in Alzheimer’s disease models"*
**作者**: Ferrer I, et al.
**摘要**: 使用PRKCB抗体在阿尔茨海默病转基因小鼠中检测PKCβ表达，发现其过度激活导致tau蛋白异常磷酸化，特异性抑制剂可改善认知功能。
---
4. **文献名称**: *"Targeting PKCβ in glioblastoma with monoclonal antibody therapy"*
**作者**: Nakashima H, et al.
**摘要**: 开发针对PRKCB的单克隆抗体，在胶质母细胞瘤细胞系中验证其结合特异性，并显示抗体通过阻断PKCβ信号通路抑制肿瘤增殖和血管生成。
---
**备注**：以上文献为示例性质，具体研究需通过PubMed或专业数据库核实。若需真实文献，建议检索关键词“PRKCB antibody”、“PKCβ inhibitor”或“PRKCB immunohistochemistry”。
The PRKCB antibody targets protein kinase C beta (PKCβ), a serine/threonine kinase belonging to the classical PKC family. PKCβ exists as two splice variants (βI and βII) and plays critical roles in intracellular signaling pathways regulating cell growth, differentiation, apoptosis, and immune responses. It is activated by diacylglycerol (DAG) and calcium, often downstream of receptor tyrosine kinases or G protein-coupled receptors. PRKCB is widely expressed in tissues, including the brain, immune cells, and vascular endothelium, and its dysregulation is implicated in cancer, diabetic complications, neurodegenerative diseases, and inflammatory disorders.
PRKCB antibodies are essential tools for studying PKCβ expression, localization, and activation in research contexts. They are used in techniques like Western blotting, immunohistochemistry, and flow cytometry to investigate PKCβ's role in diseases or signaling mechanisms. For example, elevated PKCβ activity is linked to tumor angiogenesis and chemotherapy resistance, while its inhibition shows therapeutic potential in diabetic retinopathy. Commercial PRKCB antibodies are typically validated for specificity against one or both isoforms, though users must confirm cross-reactivity given the high homology among PKC family members. Proper controls, such as knockout validation or peptide blocking, are recommended to ensure accurate interpretation.
×
